Eli Lilly and Company LLY
1,443.50 USD +17.95 (+1.26%)
At closeNov 13, 2026, 7:57 PM EST
1,439.99 -3.51 -0.24%
After hours · Nov 13, 7:57 PM ET
1,419.81 Day range 1,449.64
850.51 52-week range 1,460.00
- YTD
- +34.32%
- 1 year
- +41.12%
News
zacks.com HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.
zacks.com 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
benzinga.com Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 30.78% on an annualized basis producing an average annual return of 40.82%. Currently, Eli Lilly has a market capitalization…
reuters.com Mapping the Market: Eli Lilly shares ready to rally again Mapping the Market: Eli Lilly shares ready to rally again
benzinga.com Eli Lilly Breaks Ground On $3.5B Manufacturing Facility In Pennsylvania's Lehigh Valley; Site To Create 850 High-Wage Jobs And 2,000 Construction Jobs Facility will manufacture injectable medicines, including retatrutideSite will create 850 high-wage jobs and 2,000 construction jobsINDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company…
prnewswire.com Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company…
fool.com Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It AI could improve the drug discovery and development process. Eli Lilly has made an important move to benefit from this.
youtube.com The Big 3: JNJ, LLY, AAPL Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks…
benzinga.com Eli Lilly Wins China Approval for First GLP-1 Weight-Loss Pill, Giving It First-Mover Edge In Potential $4.5 Billion Market: Report Eli Lilly wins China approval for its first GLP-1 weight-loss pill, gaining an early edge in the country's $4.5 billion market.
reuters.com China approves Eli Lilly's weight loss pill orforglipron China approves Eli Lilly's weight loss pill orforglipron
fool.com Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company,…
benzinga.com Pfizer And Blackstone Life Sciences Enter Co-Funding Agreement Under Which Blackstone Will Pay Up To $1.5B Of Development Costs For Study Of Monthly GLP-1 Receptor Agonist Peptide Berobenatide Through 2028 Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the…
fool.com Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027? Johnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies. Eli Lilly is currently defined by explosive growth in the metabolic…
benzinga.com Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial Eli Lilly reports positive 52-week trial results showing sustained efficacy from combining Taltz and Zepbound for psoriatic arthritis.
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
benzinga.com Eli Lilly Reports 52-Week Results Showing Improved Efficacy From TOGETHER-Psa Phase 3b Open-Label Clinical Trial Evaluating Taltz-Zepbound Combination In Psoriatic Arthritis Nearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind…- benzinga.com Lilly Highlights Phase 3b Data On Taltz, Zepbound Nearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind…
prnewswire.com New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind…
247wallst.com Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.
247wallst.com Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week.
seekingalpha.com 10 Dividend Growth Stocks: November 2026 In this monthly series, I rank a selection of dividend growth stocks and present the top 10 for consideration. To rank stocks, I sort candidates by quality score. This month's top 10, led by AMAT,…
benzinga.com FDA Flags Potential Vision Loss Risk With GLP-1 Drugs, Requiring Weight-Loss Medicines Like Wegovy and Zepbound to Carry New Warning FDA requires new NAION eye warning on all GLP-1 drugs, citing potential increased risk.
prnewswire.com Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting After years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor led her to Foundayo, and why she encourages others to talk with their…
benzinga.com Jefferies Maintains Buy on Eli Lilly, Raises Price Target to $1700 Jefferies analyst Akash Tewari maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1610 to $1700.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com 11 Of 11 Sectors Rise Monday As Growth Leads All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
benzinga.com Eli Lilly Gains After Jefferies Raises Price Target to Wall Street-High $1,700 Eli Lilly is rising Monday after Jefferies raised its price target to $1,700, the highest target on Wall Street, according to Investing.com.
zacks.com Novo Up 4% in a Month: How Should Investors Approach the Stock Now? NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
zacks.com 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
benzinga.com Eli Lilly Announces Foundayo Met Primary Endpoint At Week 52 In ATTAIN-OSA Trial To Reduce Apnea-Hypopnea Index; Lowers Sleep Apnea-Specific Hypoxic Burden By Up To An Average Of 55.9% Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo…
prnewswire.com Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission…
fool.com Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence Some of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline.
benzinga.com Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery On Friday, Eli Lilly And Co. (NYSE:LLY) and Hims & Hers Health Inc. (NYSE:HIMS) announced a collaboration to broaden patient access to obesity medications Zepbound and Foundayo through the digital…
benzinga.com Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
benzinga.com Growth Lead Sectors In Friday Trading As Defensives Trail Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…
investors.com Top Funds Feast On Shell, Microsoft, Palantir And 24 More Stocks The best mutual funds place massive bets on Microsoft, Palantir and Apple. But that's just the start.- benzinga.com Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced…
prnewswire.com Lilly and Hims & Hers expand access to FDA-approved Lilly medicines Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims &…
businesswire.com Lilly and Hims & Hers expand access to FDA-approved Lilly medicines INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo…
benzinga.com LifeMD Announces Agreement For Its Pharmacies To Directly Dispense, Ship Eli Lilly's Self-Pay GLP-1 Medicines LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD's affiliated pharmacy to directly…
benzinga.com Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines Novo Nordisk (NVO) stock jumped after Q3 earnings beat estimates, driven by record Wegovy pill demand and a raised 2026 outlook.- benzinga.com Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1600 Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1440 to $1600.
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
benzinga.com JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1650 JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1500 to $1650.
benzinga.com Scotiabank Maintains Sector Outperform on Eli Lilly, Raises Price Target to $1605 Scotiabank analyst Louise Chen maintains Eli Lilly (NYSE:LLY) with a Sector Outperform and raises the price target from $1300 to $1605.- benzinga.com Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1596 Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1430 to $1596.
benzinga.com Eli Lilly 'Deserves' Stock Upside: Analyst Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
benzinga.com Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1500 Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1330 to $1500.- benzinga.com RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1600 RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1500 to $1600.